Company / Cash & Equivalents
Trulieve Cannabis Corp. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$238.8M
FY2025
5-year range
$146.7M / $238.8M
FY2021-FY2025
Trend
+15.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $227M to $239M over the past 2 years.
Based on SEC 10-K filings.
$239M in FY2025 with a 3-year CAGR of +17.6%.
Improved from $227M to $239M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +17.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 15.3% year-over-year.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $238.8M | +15.3% |
| FY2024 | $207.2M | -8.6% |
| FY2023 | $226.6M | +54.5% |
| FY2022 | $146.7M | +0.0% |
| FY2021 | $146.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026